# A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

> **NCT00386139** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 881 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren/HCTZ

## Key facts

- **NCT ID:** NCT00386139
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 881 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386139, "A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00386139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*